Sellas Life Sciences Group Inc (SLS)
$14.02
$0.32
(2.34%)
As on 04-Sep-2026 13:38EDT
Market cap
$2,668 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
22.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.4 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-1.7
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.2
-
Face value
--
-
Shares outstanding
201,945,709
10 Years Aggregate
CFO
$-286.66 Mln
EBITDA
$-305.69 Mln
Net Profit
$-310.22 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sellas Life Sciences Group Inc (SLS)
| 271.9 | 25.0 | 71.2 | 687.6 | 110.6 | 8.1 | -49.1 |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Sellas Life Sciences Group Inc (SLS)
| 262.5 | -1.9 | -55.1 | -57.3 | -4.8 | 35.1 | -93.0 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sellas Life Sciences Group Inc (SLS)
|
14.0 | 2,667.7 | 0.0 | -32.5 | -- | -31.1 | -- | 22.3 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 268.4 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 |
Shareholding Pattern
View DetailsAbout Sellas Life Sciences Group Inc (SLS)
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a... peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. Read more
-
Founder, President, CEO & Director
Dr. Angelos M. Stergiou M.D., ScD h.c.
-
Founder, President, CEO & Director
Dr. Angelos M. Stergiou M.D., ScD h.c.
-
Headquarters
New York, NY
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Sellas Life Sciences Group Inc (SLS)
What is the current share price of Sellas Life Sciences Group Inc (SLS) Today?
The share price of Sellas Life Sciences Group Inc (SLS) is $14.02 (NASDAQ) as of 04-Sep-2026 13:38 EDT. Sellas Life Sciences Group Inc (SLS) has given a return of 110.65% in the last 3 years.
What is the current PB & PE ratio of Sellas Life Sciences Group Inc (SLS)?
Since, TTM earnings of Sellas Life Sciences Group Inc (SLS) is negative, P/E ratio is not available.
The P/B ratio of Sellas Life Sciences Group Inc (SLS) is 22.32 times as on 28-Aug-2026, a 331 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-21.49 |
8.14 |
2024 |
-2.49 |
8.13 |
2023 |
-0.87 |
-4.09 |
2022 |
-1.19 |
10.11 |
2021 |
-4.25 |
4.32 |
What is the 52 Week High and Low of Sellas Life Sciences Group Inc (SLS)?
The 52-week high and low of Sellas Life Sciences Group Inc (SLS) are Rs 15.88 and Rs 1.39 as of 05-Sep-2026.
What is the market cap of Sellas Life Sciences Group Inc (SLS)?
Sellas Life Sciences Group Inc (SLS) has a market capitalisation of $ 2,668 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Sellas Life Sciences Group Inc (SLS)?
Before investing in Sellas Life Sciences Group Inc (SLS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.